Sun Pharma's new semaglutide brands, Noveltreat and Sematrinity, now in India.
Sun Pharmaceutical Industries Ltd. has launched its semaglutide brands, Noveltreat and Sematrinity, in the Indian market. These products are intended to offer more affordable options compared to existing innovator brands, with prices ranging from approximately ₹750 to ₹2,000.
The introduction of these semaglutide brands aims to provide cost-effective alternatives for patients requiring such medication in India. Semaglutide is typically used in the treatment of type 2 diabetes and, in some cases, for weight management.
By launching Noveltreat and Sematrinity at a lower price point, Sun Pharma is positioning itself to capture a significant share of the market by making the drug more accessible to a broader patient base. This move reflects a strategy to compete with established brands by offering value-priced alternatives.
About the Author
